Salarius Pharmaceuticals Inc. announced a significant update to its merger agreement with Decoy Therapeutics Inc. On June 10, 2025, the company entered into a Second Amendment to the Merger Agreement, prompted by substantial changes in market conditions. Since the execution of the original agreement in January 2025, the company's stock price has significantly decreased, affecting the exchange ratio. As a result, Salarius Pharmaceuticals' valuation was adjusted from $4.6 million to $2.31 million, leading to an increase of approximately 17 million shares of common stock to be issued to Decoy stockholders. Following this amendment, legacy stockholders of Salarius will retain 7.6% ownership, while Decoy's legacy stockholders will hold 92.4% of the combined company upon completion of the merger. This change reflects the shifting market landscape and aims to facilitate the completion of the transaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.